It has been demonstrated that in MetS patients or in those with evidence of insulin resistance, a discordance between ApoB and LDL-c is more evident and ApoB appears to be superior to LDL-c in predicting CV risk18. This evidence concerns the gene APOB and metabolic syndrome.